ACE2 and COVID-19: The safety of ACE-I/ARB use in COVID-19 patients from a Middle Eastern country, as our study showed, is consistent with the outcomes of other studies reported from different regions of the world.21 Studies have overlooked examining a potential ACE-I/ARB dose-effect on COVID19 severity.10,11,17 Different doses of ACE-I and ARB yielded variable degrees of ACE2 expressions in animal models.5 We did not detect a correlation between ACE-I or ARB doses and COVID19 severity in our study.